Interview by Amanda Wright
Why did you first think that a permanent bioconvertible IVC filter was the answer for patients with pulmonary embolism?
Vena caval filters came about in the early 1970s to prevent pulmonary embolisms. In the 1990s, they developed retrievable filters, but this involved its own risks and costs so we thought that a bioconvertible filter was best for protection during the high-risk period against pulmonary embolism.
Weight (Homepage): 1 Weight (Archive): 1Troy Trayer, DO and Jon C. George, MD
AbstractA patient presented for coronary angiography and followed by ad hoc percutaneous coronary intervention. Upon completion of the procedure, angiogram of the left common femoral artery revealed minimal disease, and an Angioseal vascular closure device was successfully deployed for hemostasis.
Weight (Homepage): 2 Weight (Archive): 2Sean P. Lyden, MD
AbstractAortoiliac stenting is the treatment of choice for aortoiliac occlusive disease. After reviewing treatment techniques, research shows that outcomes are similar for balloon expandable and self-expanding stents. Covered stents are now being studied but no published benefit exists over uncovered stenting. Secondary patency of aortoiliac intervention rivals open surgery through 3 years.
Weight (Homepage): 3 Weight (Archive): 3Madjid Chinikar, MD and Samira Arami, MD
AbstractCarotid artery stenting (CAS) is the treatment of choice in high-risk patients with extracranial carotid occlusive disease.1 Bradycardia and hypotension are well-recognized complications of this procedure and are often transient and self-limiting.
Weight (Homepage): 4 Weight (Archive): 4Interview by Amanda Wright
Tell me about your recently published study regarding the use of catheter-directed ultrasound-accelerated thrombolysis for the treatment of pulmonary embolism.
This is a really exciting new thing for me, and actually a new thing for the world for that matter, in the treatment of pulmonary embolism. Pulmonary embolism can be and frequently is a life-threatening condition and we’re taking patients now with a significant clot burden, a significant degree of debility from pulmonary embolism, and treating them with ultrasound-assisted thrombolysis, which means that we are using a drug to dissolve blood clots in combination with ultrasound technology.
Weight (Homepage): 1 Weight (Archive): 1Interview by Amanda Wright
Tell me about the recent Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis (PACIFIER) Trial and its significance for patients with femoropopliteal lesions.
The PACIFIER Trial evaluated prevention of restenosis with paclitaxel-coated PTA balloon catheters in stenosis or occlusion of femoropopliteal arteries versus a control group treated with uncoated balloons. We specifically looked at the In.Pact Pacific drug-eluting balloon (Medtronic).
Weight (Homepage): 2 Weight (Archive): 2David Orion, MD1,3, Adnan H. Siddiqui, MD1-3, Elad I. Levy, MD1-3, L. Nelson Hopkins, MD1-3
AbstractMethods of cerebral embolic protection during carotid artery stenting focusing on the newest method, proximal occlusion, are discussed in this manuscript. Proximal occlusion devices achieve cerebral protection through flow reversal from the internal carotid artery into the arterial guide sheath that is the conduit for the deployment of devices across the carotid bifurcation.
Weight (Homepage): 3 Weight (Archive): 3Vincent Varghese, MD, Richard Kovach, MD, Jon C. George, MD
AbstractPopliteal artery aneurysm (PAA) is the most commonly encountered peripheral arterial aneurysm in vascular medicine. Surgical correction has been the gold standard of therapy with endovascular techniques using covered stent grafts having comparable medium-term patency rates.
Weight (Homepage): 4 Weight (Archive): 4Cynthia Weber, MD, Robert Craig, MD, Ross Milner, MD
AbstractWe present a rare case report of a 17-year-old male who developed a brachial artery pseudoaneurysm after donating blood at his high school blood drive. We describe our operative approach and review the literature on the risks of blood donation and incidence of brachial artery pseudoaneurysms.
VASCULAR DISEASE MANAGEMENT 2012;9(1):E1–E2
Weight (Homepage): 5 Weight (Archive): 5Konstantinos Charitakis, MD, Rajesh Swaminathan, MD, Luke Kim, MD, Dmitriy N. Feldman, MD
AbstractWe present a case of coronary subclavian steal syndrome due to severely calcified left subclavian artery and prior patent left internal mammary artery (LIMA) to distal left anterior descending artery (LAD). Our patient underwent percutaneous treatment of subclavian stenosis with the AngioSculpt balloon PTA (AngioScore, Inc.) and stenting.
Weight (Homepage): 2 Weight (Archive): 2Ahmet Karabulut, MD, Mahmut Cakmak, MD, Onder Teskin, MD
AbstractA 29-year-old male patient presented with shortness of breath, palpitation, and back pain 3 years after a gunshot injury. Magnetic resonance imaging and selective angiography showed a giant pseudoaneurysm of the right subclavian artery. It extended into the right paratracheal and retrocaval regions, compressing the lung parenchyma.
Weight (Homepage): 4 Weight (Archive): 4Interview by Amanda Wright
Tell me about the Find the AAAnswers campaign and how it began.
There are about 1 and a half million people in the United States who have an undiagnosed problem called an abdominal aortic aneurysm. If they are under- or undiagnosed during the patient’s lifetime, there is a significant chance that they may rupture, and if they rupture, about 90% of the patients die.
Weight (Homepage): 1 Weight (Archive): 1Hugh B. Milteer Jr, BA, MBA1, Farrell Mendelsohn, MD2, Hutton Brantley, MD3, Jennifer Kiessling, MD1, Robert Bourge, MD1
AbstractObjective. We assessed the risk of intracerebral hemorrhage (ICH) in patients who underwent carotid artery stenting (CAS) and received glycoprotein IIb/IIIa inhibition as adjunctive antiplatelet therapy. Background. Despite smaller studies to the contrary, we report a negligible risk of ICH with adjunctive glycoprotein IIb/IIIa inhibitor use in CAS.
Weight (Homepage): 3 Weight (Archive): 3Sherif Sultan, MD, Wael Tawfick, MD, Niamh Hynes, MD
AbstractEndovascular revascularization (EVAR) is the current gold standard and first line of therapy for critical limb ischemia (CLI). However, despite the advances of EVAR, there is still concern about its capability for treating complex tibial lesions. This study aims to compare outcomes with cool excimer laser-assisted angioplasty (CELA) vs tibial balloon angioplasty (TBA) in patients with CLI TASC D.
Weight (Homepage): 2 Weight (Archive): 2
